Literature DB >> 2670521

Optimum pharmacological management of chronic rhinitis.

F E Simons1, K J Simons.   

Abstract

Pharmacological treatment of chronic rhinitis has greatly improved with the introduction of the relatively non-sedating H1-receptor antagonists such as terfenadine, astemizole, loratadine, and cetirizine, and the safe, highly efficacious topical glucocorticosteroids such as beclomethasone dipropionate, flunisolide, budesonide, fluocortin butyl, and triamcinolone acetonide. In patients whose chief complaint is rhinorrhoea, topical ipratropium bromide may be of value. Patients whose major symptom is nasal congestion will benefit from intermittent use of topically or orally administered decongestants. In patients with allergic rhinitis, sodium cromoglycate (cromolyn sodium) or nedocromil sodium applied topically intranasally have a moderate beneficial effect and are associated with a low incidence of adverse effects. Non-pharmacological treatment of chronic rhinitis cannot be ignored. Patients must avoid inhalation of cigarette smoke and other irritants. Patients with chronic allergic rhinitis should avoid antigens to which they have known sensitivity: in addition, selected patients with allergic rhinitis may benefit from immunotherapy with the offending antigen(s).

Entities:  

Mesh:

Year:  1989        PMID: 2670521     DOI: 10.2165/00003495-198938020-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  174 in total

1.  Demonstration of inhibition of mediator release from human mast cells by azatadine base. In vivo and in vitro evaluation.

Authors:  A G Togias; R M Naclerio; J Warner; D Proud; A Kagey-Sobotka; I Nimmagadda; P S Norman; L M Lichtenstein
Journal:  JAMA       Date:  1986-01-10       Impact factor: 56.272

2.  Long-term safety and efficacy of budesonide nasal aerosol in perennial rhinitis. A 12-month multicentre study.

Authors:  N Lindqvist; V H Balle; P Karma; J Kärjä; D Lindström; J Mäkinen; J Pukander; P Ruoppi; J Suonpää; W Ostlund
Journal:  Allergy       Date:  1986-04       Impact factor: 13.146

3.  Double-blind controlled crossover trial of 4% intranasal sodium cromoglycate solution in patients with seasonal allergic rhinitis.

Authors:  R K Chandra; G Heresi; G Woodford
Journal:  Ann Allergy       Date:  1982-09

4.  The use of antihistamines in patients with asthma. American Academy of Allergy and Immunology.

Authors: 
Journal:  J Allergy Clin Immunol       Date:  1988-09       Impact factor: 10.793

5.  A study of sustained action pseudoephedrine in allergic rhinitis.

Authors:  L H Hamilton; S L Chobanian; A Cato; J G Perkins
Journal:  Ann Allergy       Date:  1982-02

6.  The development of subsensitivity to chlorpheniramine.

Authors:  R J Taylor; W F Long; H S Nelson
Journal:  J Allergy Clin Immunol       Date:  1985-07       Impact factor: 10.793

7.  Significance of H1 and H2 receptors in the human nose: rationale for topical use of combined antihistamine preparations.

Authors:  C Secher; J Kirkegaard; P Borum; A Maansson; P Osterhammel; N Mygind
Journal:  J Allergy Clin Immunol       Date:  1982-09       Impact factor: 10.793

8.  Short-term efficacy trial and twenty-four-month follow-up of flunisolide nasal spray in the treatment of perennial rhinitis.

Authors:  D E Clayton; J B Kooistra; M Geller; J Ouellette; M Cohen; C E Reed; W Busse
Journal:  J Allergy Clin Immunol       Date:  1981-01       Impact factor: 10.793

9.  Comparative trial of two dose regimens of terfenadine in patients with hay fever.

Authors:  J C Murphy-O'Connor; R L Renton; D M Westlake
Journal:  J Int Med Res       Date:  1984       Impact factor: 1.671

10.  Terfenadine (Seldane) is a potent and selective histamine H1 receptor antagonist in asthmatic airways.

Authors:  P Rafferty; S T Holgate
Journal:  Am Rev Respir Dis       Date:  1987-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.